Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Bicycle Therapeutics plcNASDAQ: BCYC

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 100.0%

Gross margin was 100.0% in Q1 FY2026, up 574.0 pp from a year earlier. On a trailing-twelve-month basis it was -11.9%, up 506.2 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+490.3 pp YoY
LTMMar 2026
-11.9%+506.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+574.0 pp——
1 year+490.3 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+490.3pp

Gross Margin vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 gross margin of -11.9% is the 5th highest of the 7 companies compared; the peer median is 68.8%.
  • Its year-over-year change of +506.2 pp is the 2nd highest of 5, against a peer median of +40.5 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +1274.0 pp.
BCYC Competitors Peer median
Gross Margin for BCYC and competitors
Company Period LTM level YoY 3-year change
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202592.0% ——
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
OMEROmeros CorporationLTM Mar 2026-12.4% ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
FULCFulcrum Therapeutics, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding BCYC) 68.8%+40.5 pp+1274.0 pp

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.